Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognitive effects of adjunctive vortioxetine in early schizophrenia
2024-519778-38-00Phase 3Authorised
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of vortioxetine in Schizophrenia Spectrum and Other Psychotic Disorders (SZ) and schizophrenia (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Cognitive functioning improvement. Planned start Dec 2024; status: authorised.
02
Drugs
vortioxetine
03
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders (SZ)schizophrenia
Beyond the preview
Go deeper on 2024-519778-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519778-38-00.